:,

Christopher J Giacoletto1, Liz J Valente2, Lancer Brown2

  • 1Heligenics Inc., 10530 Discovery Dr., Las Vegas, NV 89135 USA; Nevada Institute of Personalized Medicine, University of Nevada, Las Vegas, 4505 S. Maryland Parkway, Las Vegas, Nevada, 89154 USA; School of Life Sciences, University of Nevada, Las Vegas, 4505 S. Maryland Parkway, Las Vegas, Nevada, 89154 USA.

New biotechnology
|December 25, 2025
PubMed
概括

一个新的GigaAssay通过评估酸化,准确地测量ERBB2 (HER2) 变体的致癌潜力. 这种高通量方法精确地分类功能增益变体,有助于理解HER2信号复杂性.